The Genetics and Neuroscience SIG brings together researchers who are broadly involved in the biological science of anxiety and depressive disorders. This includes clinical and basic neuroscience (electrophysiology, imaging, animal models, experimental paradigms) and genetics (twin and family studies, molecular genetics, endophenotypes). The SIG provides ADAA members with opportunities to network, share ideas, form collaborations, and update one another and the broader ADAA community on the state of the genetics and neuroscience field. The group is comprised of a diverse array of clinicians, researchers, and clinician-researchers across the student, postdoctoral scholar/clinical trainee, and faculty/practitioner levels.

Recent SIG activities include: (1) Establishing a repository of information on measures relevant to the genetics and neuroscience study of anxiety and depression, so that anyone in the ADAA community can learn what measures are out there, how to find them, and how they link to other units of analysis within the Research Domain Criteria (RDoC) domain, and (2) Providing monthly updates on articles relevant to the group’s focus.

At this year’s ADAA meeting in Washington DC., the SIG will host a symposium on Ketamine as a Novel Approach for Treatment-Resistant Depression and Anxiety.” Drs. Carlos Zarate (National Institute of Mental Health) and Chadi Abdallah (Yale University) will present, followed by an interactive discussion.

If you’re interested in joining this SIG, please login to your member account and choose Groups under My Membership on the right hand navigation. Have a question about the member platform? Please contact Lisa Patterson, ADAA Membership Director. 

Please view the ADAA SIG Guidelines for responsibilities and expectations. 

SIG Co-Chairs:

  • Lynnette A. Averill, PhD 
  • Karmel Choi, PhD
  • Sahib Khalsa, MD, PhD
  • Sanne JH van Rooij, PhD

Board Liasion:
Sheila Rauch, PhD, ABPP

2017-2018 Annual Report

Accomplishments 

  1. We informed the membership of the SIG activities at this year’s meeting.
  2. We asked past SIG meeting attendees (n=60) to confirm their intent to continue to participate so we could update the membership list and encourage more activity from junior members. This resulted in the current tally of 51 members. 
  3. We established toolbox of information on measures relevant to genetics and neuroscience studies of anxiety and depression, so that anyone in the ADAA community can learn what measures are out there, how to find them, and how they link to other units of analysis within the Research Domain Criteria domains. After we created this dropbox repository, we asked feedback from the GAN SIG members, and asked them to add any measures that were missing, thereby making it an interactive tool for all researchers to use.
  4. We posted monthly updates about recently published studies via blog and the GAN-SIG webpage. Posts covered the role of cannabinoids in anxiety, ketamine for depression, propranolol for PTSD, and prazosin for PTSD.
  5. For this year's ADAA meeting in Washington DC, we organized a symposium on “Ketamine as a Novel Approach for Treatment-Resistant Depression and Anxiety.” We invited two experts in this field to discuss this topic from a genetics and neuroscience perspective: Drs. Carlos Zarate (National Institute of Mental Health) and Chadi Abdallah (Yale University). Their presentation will be followed by an interactive discussion.

Ongoing/plans for the future

  1. We will continue our monthly updates on articles relevant to the group’s focus by posting these articles on the ADAA webpage. We also include an explanation of its relevance to the members of the GAN-SIG.
  2. Start our search for new leaders of the GAN-SIG,  such that we can transition after two years
  3. Organize the GAN-SIG symposium for the 2019 ADAA meeting; decide on a topic and and invite experts in the field of neuroscience and genetics to give a presentation about this their research related to this topic.